Roundup MDL Durnell Hearing: What Judge Chhabria Will Decide on November 16 and Which Claims Survive
Judge Vince Chhabria hears Monsanto's first post-Durnell dismissal motions in the Roundup MDL on Monday, November 16, 2026. The Roundup MDL Durnell hearing will show whether negligence and design defect claims outlive the Supreme Court's label ruling for the 916 federal cases left.
Torts Desk··22 min read

The Roundup MDL Durnell hearing in one paragraph
On Monday, November 16, 2026, U.S. District Judge Vince Chhabria of the Northern District of California hears argument on Monsanto's first round of motions to end federal Roundup cases under the Supreme Court's June 25, 2026 decision in Monsanto Co. v. Durnell, reported as covering one group of cases and eight individual plaintiffs. The Roundup MDL Durnell hearing is the first time the judge who has run In re Roundup Products Liability Litigation, MDL No. 2741, since 2016 will take argument on whether negligence, design defect and warranty claims survive a ruling that, on its face, killed only label-based failure-to-warn claims.
The stakes are concrete. The Judicial Panel on Multidistrict Litigation's November 2, 2026 statistics report lists 916 actions still pending in MDL 2741, according to two independent case trackers, down from 3,925 on September 1 and 1,104 on October 1. Most of the drop reflects claimants moving toward the $7.25 billion King v. Monsanto class settlement, which still awaits final approval in the Circuit Court of the City of St. Louis. The 916 who remain are, by definition, the cases that did not settle, and the November 16 argument decides how many of them get a trial.
This briefing explains what is on the calendar, what Durnell did and did not decide, what the three amicus briefs argued, how other courts have split the same question since June, and what each side's lawyers should watch for when the ruling comes.
What is happening at the Roundup MDL hearing on November 16, 2026?
Judge Chhabria is scheduled to hear Monsanto's supplemental motions for summary judgment and dismissal addressed to the scope of Durnell. Tracker reporting on the docket describes the first-round motions as directed at one defined group of cases plus eight individually named plaintiffs, and places the motions, Monsanto's replies and the outside amicus briefs in a run of docket entries numbered in the 22,500 to 22,750 range. A schedule order circulated by plaintiffs' counsel earlier in the year lists a hearing on Monday, November 16 at 1 p.m.
Three features of the hearing matter more than the date.
- It is a merits hearing on preemption, not a case-management conference. For the first time since the Supreme Court's mandate issued on July 27, 2026, the MDL court will hear the parties argue whether specific, pleaded state-law claims are "requirements for labeling or packaging" within the meaning of FIFRA's preemption clause.
- It is limited to a first tranche. The court has staged the post-Durnell motions. The CourtListener docket for the MDL shows that at a September 22, 2026 case management conference the court set motions to dismiss directed to "Category 3 and 4" cases for filing by February 12, 2027, with a hearing on March 19, 2027 by videoconference. Tracker reporting also describes a second group of renewed summary judgment motions due December 1 with a hearing to follow in February. The November 16 ruling will therefore set a template rather than end the docket.
- It follows invited amicus briefing. On October 20, 2026, Judge Chhabria asked outside parties to brief whether "negligence, design defect, or express or implied warranty claims against Monsanto under Florida, Ohio, North Carolina, Mississippi, Georgia, or Arizona law are preempted by federal law." Three briefs were filed in response, according to Law.com's November 2 report. That choice of states tells practitioners which bodies of product liability law the first ruling is likely to apply.
The judge is not required to rule from the bench, and nothing in the public reporting suggests he will. He has a record of written, heavily reasoned orders in this MDL, and the amicus invitation signals that he expects his answer to be read well beyond San Francisco.
Background: how the Roundup MDL got here
MDL No. 2741 was created by the JPML in October 2016 and assigned to Judge Chhabria. It gathered federal claims that glyphosate-based Roundup herbicides cause non-Hodgkin lymphoma (NHL) and that Monsanto, acquired by Bayer AG in 2018, failed to warn users. Over its life, more than 5,300 actions have been transferred into the MDL. The litigation's highest-profile federal result was the 2019 Hardeman bellwether, and the federal docket has been shaped since 2020 by repeated waves of settlements, the court's refusal in 2021 to approve a class deal for future claimants, and the long-running fight over common benefit assessments.
The Supreme Court's grant of certiorari in Durnell, a Missouri state-court case, changed the federal calculus. Bayer had made clear that it regarded a favorable preemption ruling as the tool to end the MDL. In July 2026, shortly after the decision, Reuters reported that Bayer told the court the federal litigation had "no reason to exist" after the ruling, and that the consolidated docket then held close to 4,000 cases. Judge Chhabria's response, as reported at the time, was to call both sides' initial submissions "unsatisfying" and to direct them to prepare to address the harder legal questions: which claims, under which states' laws, actually depend on a label.
That is the question the November 16 hearing finally reaches.
What did Monsanto v. Durnell decide?
Durnell held 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act preempts a state-law failure-to-warn claim that would require Monsanto to put a cancer warning on Roundup's label when the EPA-approved label carries none. Justice Brett Kavanaugh wrote for the Court, joined by Chief Justice John Roberts and Justices Clarence Thomas, Samuel Alito, Sonia Sotomayor, Elena Kagan and Amy Coney Barrett; Justice Thomas also filed a concurrence. Justice Ketanji Brown Jackson dissented, joined by Justice Neil Gorsuch.
The statutory hook is 7 U.S.C. § 136v(b), which bars states from imposing "any requirements for labeling or packaging in addition to or different from those required under" FIFRA. The Court reasoned that because John Durnell's Missouri claim would impose a labeling requirement "in addition to or different from" the label EPA required, the claim was expressly preempted. The majority drew on Bates v. Dow Agrosciences LLC, 544 U.S. 431 (2005), the Court's earlier FIFRA preemption case, and leaned on the medical-device preemption reasoning of Riegel v. Medtronic, Inc. The dissent argued that the majority misread what FIFRA requires and left Durnell without a remedy.
Two limits on the holding drive everything that follows:
- The claim before the Court was a warning claim. Durnell's jury in the City of St. Louis had awarded him $1.25 million on strict liability failure to warn. It did not find for him on his other theories, so design defect and negligence were never before the Justices.
- Bates survives. Bates held that FIFRA does not preempt state claims that are not premised on labeling or packaging requirements, such as claims for defective design, defective manufacture, negligent testing or breach of express warranty, and that state labeling rules that "parallel" federal misbranding standards are not preempted. Nothing in Durnell overrules that framework. The fight is about which side of the Bates line each remaining Roundup claim falls on.
The circuit split Durnell resolved, and why it matters for Judge Chhabria
Durnell settled a split among the federal courts of appeals over Roundup warning claims, and one side of that split was the Ninth Circuit, the court that will review whatever Judge Chhabria decides. In Hardeman v. Monsanto Co., 997 F.3d 941 (9th Cir. 2021), the Ninth Circuit affirmed Edwin Hardeman's federal bellwether verdict and held that his California failure-to-warn claim was not preempted because it paralleled FIFRA's own misbranding prohibition. The Supreme Court declined to review that decision in 2022. The Eleventh Circuit, sitting en banc in Carson v. Monsanto Co., 92 F.4th 980 (11th Cir. 2024), likewise rejected Monsanto's preemption defense. The Third Circuit went the other way in Schaffner v. Monsanto Corp., 113 F.4th 364 (3d Cir. 2024), holding a Pennsylvania failure-to-warn claim preempted because it would require a label different from the one EPA approved.
Durnell sided with the Third Circuit on the warning question. That has two consequences for the November 16 hearing.
First, the Ninth Circuit's Hardeman reasoning on parallel warning claims no longer protects failure-to-warn counts in the MDL, so the plaintiffs' bar in San Francisco has to argue from Bates rather than from circuit precedent. Second, Hardeman addressed only the warning claim as well. Nothing in Hardeman, Carson or Schaffner squarely decided whether a Roundup design defect or negligent-testing claim is a labeling requirement. The circuit precedent that would ordinarily guide a district judge on that question does not exist, which is one reason Judge Chhabria sought outside briefing rather than ruling on the parties' papers alone.
There is also a structural point. MDL judges apply the law of the transferor circuit on questions of state law and the law of their own circuit on questions of federal law. Preemption under FIFRA is a federal question, so the Ninth Circuit's view will ultimately govern the MDL's answer, even for plaintiffs whose cases came from Florida, Georgia or Mississippi in the Eleventh Circuit, or Ohio in the Sixth. Whether a given state's duty is "really" a labeling duty, however, requires an accurate account of that state's law, which is where the six-state amicus question comes in. Once the cases are remanded, the transferor courts will apply their own circuits' reading of Durnell, so a Ninth Circuit answer will be influential but not binding nationwide.
Does the Durnell decision end all federal Roundup lawsuits?
No. Durnell ended Roundup failure-to-warn claims that depend on adding a cancer warning to the label, but it did not decide whether design defect, negligence or warranty claims are preempted, and no federal court has dismissed the Roundup MDL wholesale on the strength of it. Whether those remaining claims survive in the 916 pending federal cases is precisely what the Roundup MDL Durnell hearing begins to answer.
Monsanto's position, as described in public reporting since July, is that what survives in most Roundup complaints is a repackaged warning claim. If the alleged defect is that users were not told glyphosate might cause cancer, the argument runs, the claim is a labeling claim whatever it is called, and Durnell bars it. Plaintiffs answer that a claim about how a formulation was designed, what surfactants were used, how the product was tested, or what Monsanto knew and did with that knowledge is not a demand for a different label at all.
The answer may not be uniform. Because preemption under § 136v(b) asks whether a state duty is a labeling requirement, the result can turn on how each state defines negligence and product defect. That is why Judge Chhabria's October 20 order named six states rather than asking an abstract federal question.
Which Roundup claims survive Monsanto v. Durnell?
On the current record, label-based failure-to-warn claims are gone, while design defect, negligence, warranty and fraud theories remain live unless a court finds that they are warning claims in disguise. Courts that have ruled since June have split the difference rather than dismissing cases outright. The table below sets out how each theory has fared.
| Claim theory | Effect of Durnell | Post-June 2026 rulings and results |
|---|---|---|
| Strict liability failure to warn (label) | Preempted where the claim would require a cancer warning EPA did not require | Supreme Court reversed Durnell's $1.25M verdict; on October 13, 2026 the Court vacated Mike Dennis's $28M California judgment, a warnings-only verdict, for reconsideration under Durnell |
| "Label-adjacent" warning theories (point-of-sale, advertising) | Contested; treated as warnings in disguise by at least one federal court | D. Idaho (Judge David Nye, reported October 7, 2026) barred Merril Hoge's failure-to-warn claim as "label-adjacent" |
| Negligence | Not decided by Durnell; survives if not premised on labeling | Hoge's negligence claim held "not wholesale pre-empted" and allowed to proceed; AAJ amicus argues it remains viable |
| Design defect | Not decided by Durnell; Bates treats design claims as outside § 136v(b) | Tried to a jury in Aretino v. Monsanto (St. Louis County); unanimous defense verdict October 29, 2026 on the merits, not on preemption |
| Express or implied warranty | Express warranty expressly preserved by Bates; implied warranty contested | Among the six-state questions posed in the October 20, 2026 amicus order |
| Fraud and misrepresentation | Depends on whether the misstatement is on the label or elsewhere | Rejected by the Aretino jury on the merits; pleaded in many remaining MDL complaints |
Two lessons from the table. First, the claims that survive Durnell are not necessarily claims plaintiffs win: Aretino went to verdict on design defect, negligence and fraud and produced a defense verdict within hours of closing arguments, the fifth straight Monsanto win in St. Louis County. Second, the most important post-Durnell federal ruling so far, the Idaho decision in Hoge's case, drew a line inside the warning category rather than at its edge, which is the kind of claim-by-claim sorting Judge Chhabria now has to do at scale.
What did the amicus briefs argue about Durnell preemption?
Three amicus briefs were filed after Judge Chhabria's October 20 invitation, according to Law.com. On the plaintiffs' side, the American Association for Justice, the largest organization of the plaintiffs' trial bar, told the court that Durnell leaves several viable claims for Roundup plaintiffs and did not create a "new preemption regime." On the defense side, the U.S. Chamber of Commerce and other business groups urged the court to limit further litigation.
The AAJ framing is significant because it ties the case to Bates. If Durnell is read as a routine application of § 136v(b) to a warning claim, then Bates's preservation of design defect, negligent testing and express warranty claims controls everything else. The Chamber's framing, by contrast, invites the court to read Durnell's reasoning, including its reliance on Riegel, as reaching any state-law theory whose practical effect would be to force a label change. Public reporting has not detailed the third brief's authorship or the Chamber brief's state-by-state analysis, and the briefs' full text was not publicly circulated as of this weekend.
What the court is not likely to get from either side is a simple answer for all six states. Florida, Ohio, North Carolina, Mississippi, Georgia and Arizona each have their own product liability statutes and case law on what makes a product "defective" and whether a negligence claim can be premised on failure to test or failure to reformulate. A ruling that, for example, Ohio's statutory design defect theory is not a labeling requirement while a particular Georgia negligence claim pleaded around warnings is one, would be consistent with both Durnell and Bates.
Why those six states?
The October 20 order did not explain the selection, and nothing in public reporting ties the six states to particular plaintiffs. The most plausible reading, given the court's practice of grouping cases, is that the first-round motions involve plaintiffs whose claims are governed by those states' laws. That is an inference, not a reported fact, and practitioners with clients in other states should not assume that the November 16 ruling will be dispositive for them. It will, however, be persuasive. Most states share one of two basic tests for design defect (consumer expectations or risk-utility), and a ruling on how Durnell interacts with each test will be cited in every remaining Roundup case, state or federal.
How many Roundup cases are still pending in the federal MDL?
According to the JPML's November 2, 2026 statistics report, as relayed by two independent case trackers, 916 actions remain pending in MDL 2741. That compares with 1,104 on October 1 and 3,925 on September 1, 2026. The table puts the decline in context.
| Date | Event | MDL 2741 pending actions |
|---|---|---|
| June 25, 2026 | Monsanto Co. v. Durnell decided, 7-2 | Close to 4,000 (Reuters, July) |
| July 27, 2026 | Supreme Court judgment and mandate issue | — |
| September 1, 2026 | JPML monthly report | 3,925 |
| September 14, 2026 | Final fairness hearing on the $7.25B King class settlement in St. Louis | — |
| September 22, 2026 | MDL case management conference sets Category 3 and 4 schedule | — |
| October 1, 2026 | JPML monthly report | 1,104 |
| October 20, 2026 | Chhabria invites amicus briefs on six states' law | — |
| October 29, 2026 | Aretino defense verdict, St. Louis County | — |
| November 2, 2026 | JPML monthly report; AAJ amicus reported | 916 |
| November 16, 2026 | Hearing on first-round Durnell motions | — |
| February 12, 2027 | Deadline for Category 3 and 4 dismissal motions | — |
| March 19, 2027 | Hearing on Category 3 and 4 motions (videoconference) | — |
Two cautions apply to these numbers. First, the JPML report counts docketed federal actions, not people; some actions have multiple plaintiffs, and many more Roundup claims sit in state courts in Missouri, Pennsylvania and California. Bayer has put its total exposure at roughly 65,000 unresolved claims across state and federal courts, a figure that is not comparable to the MDL count. Second, the reports do not explain why cases left the docket. The timing, a fall of 2,821 between September and October, coincides with the King settlement process rather than any court ruling.
When will Judge Chhabria rule on the Roundup dismissal motions?
There is no deadline. Federal judges are not required to rule on summary judgment within any fixed period, and Judge Chhabria has historically issued written opinions in the Roundup MDL weeks after argument rather than ruling from the bench. Because the Category 3 and 4 motions are not due until February 12, 2027, a written ruling on the first-round motions before then would give both sides a template for the second round, which suggests the court has an interest in deciding the November 16 motions in the weeks that follow.
A ruling granting summary judgment on some or all claims of the eight named plaintiffs would be a final judgment as to them only if the court enters a separate judgment under Federal Rule of Civil Procedure 54(b) or disposes of their cases entirely. Otherwise, an appeal to the Ninth Circuit would ordinarily wait. That matters because both sides have an incentive to get an appellate answer on Durnell's scope quickly; the Ninth Circuit has already been asked to review the MDL's 8% common benefit assessment in a separate appeal that plaintiffs' firms pressed in an October 22, 2026 filing.
How does the MDL hearing affect the $7.25 billion Roundup settlement?
Directly, it does not. The King v. Monsanto class settlement is pending in Missouri state court, not in the MDL, and Judge Timothy Boyer of the Circuit Court of the City of St. Louis has had it under submission since the September 14, 2026 fairness hearing. The deal would pay up to $7.25 billion over as long as 21 years, with individual awards across nine tiers. Bayer CEO Bill Anderson said on November 3, 2026 that the company expects approval "before Christmas" and that it "could be any week now."
Indirectly, the hearing matters a great deal. Anderson also said that many claimants who opted out of King, and their lawyers, are trying to rejoin after Durnell, and that he expects the opt-out count to fall through an administrative process after a final ruling. A strong Monsanto win on November 16 would make remaining in the MDL less attractive and push more opt-outs back toward the class. A ruling that preserves design defect and negligence claims would do the reverse: it would give opt-outs a federal forum for claims a jury might hear, and it would strengthen objectors who argue that the class deal undervalues claims that survived the Supreme Court. Bayer holds a right to walk away from King if opt-outs are excessive, so the size of the federal docket after the ruling feeds back into the settlement's stability.
Judge Chhabria has been openly skeptical of the King deal. In April 2026 he reportedly called the proposed settlement "filthy," and in May he expressed "grave concerns" about whether a Missouri court could bind out-of-state users and people not yet diagnosed, while declining to enjoin it. His preemption ruling will be read in St. Louis for what it says about the value of the claims the class would release.
What other courts have said since June
The November 16 hearing does not happen in a vacuum. Since Durnell, state and federal courts have issued a series of rulings that frame the arguments Judge Chhabria will hear.
- District of Idaho, Hoge v. Monsanto. Judge David Nye, as reported on October 7, 2026, dismissed former NFL player Merril Hoge's failure-to-warn claim as a "label-adjacent" theory but held his negligence claim "not wholesale pre-empted," allowing him to argue that factors other than labeling establish liability. The case had passed through MDL 2741 before returning to Idaho.
- District of Massachusetts. In July 2026, U.S. District Judge Margaret Guzman said at a hearing that Durnell appeared limited to claims based on Roundup's labeling, and Law360 reported that the case might still head toward trial. On November 13, 2026, Law360 reported that a Roundup user with NHL told a Massachusetts federal judge that the Supreme Court's decision barring label-based claims should not defeat his suit, showing that the same arguments are now being briefed in parallel outside the MDL.
- Eleventh Circuit, Salas. On remand after Durnell, the parties jointly moved for summary adjudication and reversal, agreeing that Durnell resolved the preemption issue in Monsanto's favor in that warnings-based case, and the court of appeals agreed.
- Supreme Court, Dennis. On October 13, 2026, the Court granted Monsanto's petition, vacated the California Court of Appeal's affirmance of Mike Dennis's $28 million judgment, and remanded in light of Durnell. Dennis's jury had found for Monsanto on design defect and negligence and for Dennis only on failure to warn.
- St. Louis County, Aretino v. Monsanto. The first post-Durnell Roundup trial went to the jury on design defect, negligence and fraud and ended in a unanimous defense verdict on October 29, 2026. Plaintiffs' counsel had asked for $10 million to $30 million for each of three Florida plaintiffs.
The pattern is consistent: courts are not treating Durnell as a docket-ending ruling, but they are trimming warning theories aggressively and leaving the surviving claims to be tried on the merits, where Monsanto has recently done well.
The arguments to expect on November 16
Based on the positions the parties and amici have taken publicly, the argument is likely to focus on four questions.
1. Is a negligence claim a labeling claim? Monsanto will argue that a negligence count alleging that the company failed to warn, or failed to disclose testing results, is the failure-to-warn claim by another name. Plaintiffs will point to negligence theories that do not depend on the label at all, such as negligent testing, negligent formulation, or failure to reformulate with safer surfactants, and to Bates's statement that claims for negligent testing are not labeling requirements.
2. Is a design defect claim really about the label? Under a consumer-expectations test, the question is whether the product was more dangerous than an ordinary consumer would expect, and that expectation is shaped by what the label says. Monsanto can argue that such a claim effectively demands a warning. Under a risk-utility test, the question is whether a safer alternative design existed, which looks less like a labeling requirement. Which test each of the six states uses may decide the outcome state by state.
3. Is "stop selling" an alternative design? Defendants in pharmaceutical cases have long argued that a claim that a product should not have been sold at all, or should have been reformulated in a way requiring new federal approval, is preempted. Expect Monsanto to argue that glyphosate itself is the alleged defect and that any reformulation would require EPA registration, and expect plaintiffs to respond that FIFRA, unlike the drug laws at issue in Mutual Pharmaceutical Co. v. Bartlett, has no comparable bar on manufacturers changing a formulation through the registration process.
4. What about warranty and fraud? Bates treated express warranty claims as outside FIFRA preemption because the manufacturer voluntarily makes the promise. Implied warranty claims, which rest on merchantability, and fraud claims premised on statements in advertising or public communications, are less settled. The six-state framing means the court may need to answer these on a state-specific basis.
What it means for plaintiffs' counsel, Monsanto and the wider mass tort bar
For plaintiffs' firms with MDL 2741 inventory. The ruling will determine which pleaded theories are worth carrying to remand and trial. Firms with clients in Florida, Ohio, North Carolina, Mississippi, Georgia and Arizona will get the most direct guidance; others will get a strong signal. The practical work is in the pleadings: complaints drafted before Durnell typically lead with failure to warn and fold warnings language into negligence and design counts. Those that can show a non-label theory, supported by expert evidence on formulation or testing, are best placed to survive. The Aretino verdict is a reminder that surviving preemption is the first hurdle, not the last.
For opt-outs from the King settlement. The hearing's outcome will directly affect the value of staying out. A narrow reading of Durnell preserves leverage; a broad reading reduces it and makes the administrative path back into the class, which Bayer's CEO has said many opt-outs are exploring, more attractive. Timing matters because final approval of King could come within weeks.
For Monsanto and Bayer. A favorable ruling would let Bayer argue that the federal docket is a residue of weak cases and press its view that the MDL has outlived its purpose, while the King deal handles the state-court inventory. An unfavorable ruling would mean a continuing federal docket with remand trials on design and negligence theories in multiple districts.
For the wider mass tort and products bar. The Durnell majority noted that several other federal statutes use similar preemption language, and the Chamber's position invites a broad reading. How Judge Chhabria applies Durnell to negligence and design defect claims will be cited in pesticide cases such as the chlorpyrifos and paraquat litigation, and by defendants in other regulated-product cases that rely on express preemption clauses modeled on the same "in addition to or different from" wording. Plaintiffs' lawyers in those dockets should read the ruling for how it treats Bates.
For funders and referral partners. Third-party litigation funding and case-acquisition decisions in the Roundup docket have been on hold since June. The November 16 ruling, and the follow-on Category 3 and 4 decision after March 19, 2027, are the events that will reprice the remaining federal inventory.
The procedural map after November 16
Whatever the court decides, the federal Roundup docket will move on several tracks at once in the coming months:
- The first-round ruling. A written order on the November 16 motions, likely addressing the eight named plaintiffs and the identified group individually or by state.
- The second round. Renewed summary judgment motions for a second group reported as due December 1, with argument reported for February 2027.
- Category 3 and 4 cases. Dismissal motions due February 12, 2027 and a March 19, 2027 hearing by videoconference.
- The King settlement. A final approval ruling from Judge Boyer in St. Louis, followed by any appeals; settlement summaries tie the claims deadline to 180 days after appeals are resolved.
- The common benefit appeal. The Ninth Circuit's handling of plaintiffs' firms' challenge to the MDL's 8% common benefit holdback.
- Remand trials and state trials. Any surviving federal cases will eventually be suggested for remand to their home districts, while state courts continue to try design defect cases on the Aretino model.
Frequently asked questions
What is the Roundup MDL Durnell hearing?
It is the November 16, 2026 hearing before Judge Vince Chhabria in MDL No. 2741 on Monsanto's first round of motions arguing that Monsanto Co. v. Durnell requires dismissal or summary judgment on remaining Roundup claims, reported as covering one group of cases and eight individual plaintiffs.
Are Roundup lawsuits over after the Supreme Court ruling?
No. Durnell barred failure-to-warn claims that would require a cancer warning missing from the EPA-approved label, but it did not decide negligence, design defect or warranty claims, and 916 federal cases remained pending as of November 2, 2026, with tens of thousands more in state courts.
Can I still file a Roundup lawsuit for non-Hodgkin lymphoma?
New claims face both preemption and statute of limitations questions, and claims covered by the King class settlement are governed by its terms if it is approved. Whether a particular claim can proceed depends on the theory pleaded, the governing state's law and the claimant's diagnosis date; that is a question for a licensed lawyer, not a general news briefing.
What happens if Judge Chhabria grants Monsanto's motions?
The affected plaintiffs' claims would be dismissed or decided against them to the extent the court finds them preempted, and the reasoning would be applied to similar claims in the second-round and Category 3 and 4 motions. Plaintiffs could seek review in the Ninth Circuit once there is an appealable judgment.
What happens if he denies them?
The surviving negligence, design defect or warranty claims would move toward expert discovery, remand and trial, and the ruling would strengthen opt-outs and objectors' arguments about the value of claims released by the King settlement.
Which states' laws does the first ruling address?
Judge Chhabria's October 20, 2026 amicus order asked about negligence, design defect and express or implied warranty claims under the laws of Florida, Ohio, North Carolina, Mississippi, Georgia and Arizona, so the first ruling is expected to analyze those six states' product liability law.
How many Roundup cases are left in the federal MDL?
The JPML's November 2, 2026 report lists 916 pending actions in MDL 2741, down 188 from October and down from 3,925 on September 1, 2026.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Roundup MDL Preemption Fight: Judge Chhabria Asks Amici Whether Durnell Bars Design and Negligence Claims
Judge Vince Chhabria has invited amicus briefs on whether FIFRA preempts Roundup negligence, design defect and warranty claims under the law of six states. The Roundup MDL preemption ruling will decide how many of the 1,104 remaining federal cases survive Monsanto v. Durnell.
Torts Desk · 17 min

Roundup Trial Verdict: Monsanto Wins Aretino, the First Jury Test of Design Defect Claims After Durnell
A unanimous St. Louis County jury cleared Monsanto on October 29 of the design defect, negligence and fraud claims of three women with non-Hodgkin lymphoma. Their lawyer had asked for up to $30 million each. The Roundup trial verdict lands while a judge weighs Bayer's $7.25 billion class deal.
Torts Desk · 19 min

Merril Hoge Roundup Lawsuit Survives Durnell: Idaho Judge Keeps Negligence Claim, Bars Failure to Warn
A federal judge in Idaho has refused to throw out former NFL running back Merril Hoge's Roundup lawsuit under Monsanto v. Durnell, letting his negligence claim proceed while barring a 'label-adjacent' failure-to-warn theory. It is a federal template for how the remaining Roundup cases will be sorted.
Torts Desk · 12 min